Labcorp Q3 Revenue Rises 6.9%; Adjusted EPS Climbs 14.5% and Guidance Increases
Labcorp reported Q3 2026 revenue of $3.81B, up 6.9% YoY, and adjusted EPS of $4.78, up 14.5%. Net income was $262.8M. The company raised full-year guidance for revenue growth and adjusted EPS to $18.30–$18.70. Diagnostics and Biopharma segments showed growth, and Labcorp announced FDA approvals and acquisitions.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance are likely to drive immediate buying interest, especially from investors focused on health‑care earnings momentum.
Market read
The report provides fresh, material information that can affect Labcorp's stock price and the health‑care sector.
What to watch
Potential regulatory scrutiny of new tests and integration risk from recent acquisitions.
Background
Labcorp's Q3 earnings release includes revenue growth across its Diagnostics Laboratories and Biopharma Laboratory Services segments, plus several FDA approvals and acquisitions.
Ticker impact
Labcorp reported Q3 2026 revenue up 6.9% YoY and raised full-year guidance for revenue and adjusted EPS.
likely upward pressure as investors price in higher revenue growth and EPS outlook
The company posted better-than-expected results and increased guidance, a classic catalyst for short-term price appreciation.
Market effects
Positive for the broader health‑care diagnostics sector as Labcorp's growth may signal rising demand for lab services.
U.S. markets may see a modest lift in health‑care indices.
Limited to U.S. and global diagnostic service providers.
Counterpoint
If the guidance increase is already priced in, the stock could face a short‑term pullback.
Key entities
- companyLabcorp
U.S. health‑care diagnostics provider (ticker LH).
